GlaxoSmithKline said Monday it has submitted a biologics license application with the Food and Drug Administration seeking approval for its experimental shingle vaccine.
Analysts have projected the new drug candidate, called Shingrix, could develop into a $1 billion a year product — if it receives regulatory approval.
Shingles is an acute and painful inflammation of nerve cells that occurs as a result of reactivation of latent chickenpox virus. The condition typically presents itself as a painful, itchy rash that develops on one side of the body. Almost one out of every three people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. The Centers for Disease Control and Prevention estimates 1 million cases of shingles occurs each year in the United States.
To read the full article, click here.
For more business news, visit Philadelphia Business Journal.
